Little information is available from real-life studies evaluating the efficacy of guselkumab in moderate-to-severe psoriasis. In this real-life study, we retrospectively examined a database of 52 patients with moderate-to-severe psoriasis treated with guselkumab (100 mg, s.c.) and followed for 1 year. Disease severity and treatment response was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 20, 28, 36, 44, and 52 weeks. Predictors of a PASI response were evaluated by univariate and multivariate regression. After 12 months, 84.2% of patients (mean age 51.3 +/- 14.1 years) treated with guselkumab achieved a PASI score of <3. Furthermore, PASI score decreased from 20 +/- 13.3 at baseline to 4.4 +/- 4.7 and 2.7 +/- 3.9 at 12 and 20 weeks, and PASI 75, 90, and 100 response was achieved in 84.2%, 78.9%, and 63.2% of patients respectively at 12 months. Stepwise multivariate regression analysis revealed that previous biological treatment and the presence of comorbidities were associated with poorer response between 28-44 weeks, however the presence of obesityper sewas not associated with poorer response. Difficult-to-treat areas were also improved as early as 12 weeks following guselkumab. Guselkumab was observed to be effective and safe in patients with moderate-severe chronic psoriasis in a real world-setting.

Galluzzo, M., Tofani, L., Lombardo, P., Petruzzellis, A., Silvaggio, D., Egan, C.g., et al. (2020). Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. JOURNAL OF CLINICAL MEDICINE, 9(7), 1-16 [10.3390/jcm9072170].

Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study

Galluzzo, Marco;Bianchi, Luca;Talamonti, Marina
2020-07-09

Abstract

Little information is available from real-life studies evaluating the efficacy of guselkumab in moderate-to-severe psoriasis. In this real-life study, we retrospectively examined a database of 52 patients with moderate-to-severe psoriasis treated with guselkumab (100 mg, s.c.) and followed for 1 year. Disease severity and treatment response was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 20, 28, 36, 44, and 52 weeks. Predictors of a PASI response were evaluated by univariate and multivariate regression. After 12 months, 84.2% of patients (mean age 51.3 +/- 14.1 years) treated with guselkumab achieved a PASI score of <3. Furthermore, PASI score decreased from 20 +/- 13.3 at baseline to 4.4 +/- 4.7 and 2.7 +/- 3.9 at 12 and 20 weeks, and PASI 75, 90, and 100 response was achieved in 84.2%, 78.9%, and 63.2% of patients respectively at 12 months. Stepwise multivariate regression analysis revealed that previous biological treatment and the presence of comorbidities were associated with poorer response between 28-44 weeks, however the presence of obesityper sewas not associated with poorer response. Difficult-to-treat areas were also improved as early as 12 weeks following guselkumab. Guselkumab was observed to be effective and safe in patients with moderate-severe chronic psoriasis in a real world-setting.
9-lug-2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Psoriasis
Psoriasis Area and Severity Index (PASI)
biological drugs
guselkumab
real-life
Galluzzo, M., Tofani, L., Lombardo, P., Petruzzellis, A., Silvaggio, D., Egan, C.g., et al. (2020). Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. JOURNAL OF CLINICAL MEDICINE, 9(7), 1-16 [10.3390/jcm9072170].
Galluzzo, M; Tofani, L; Lombardo, P; Petruzzellis, A; Silvaggio, D; Egan, Cg; Bianchi, L; Talamonti, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
jcm-09-02170 Use of Guselkumab.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 6.53 MB
Formato Adobe PDF
6.53 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/255096
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 56
social impact